Why is Sagimet Biosciences stock rallying today?

Sagimet Biosciences stock surged 3.5% today after the company unveiled promising long-term efficacy data for its oral fatty acid synthase inhibitor, denifanstat, used in treating acne. The data came from a Phase 3 clinical trial conducted by Ascletis BioScience Co. Ltd. in China. The study showed a 57% treatment-success rate after 52 weeks, with acne lesions decreasing by 72% and inflammatory lesions declining 77%.

Participants remained in good health during the trial with no serious adverse events or permanent discontinuations attributed to the drug. Simultaneously, Sagimet announced a significant capital raise, selling approximately $115 million in Series A common stock and pre-funded warrants. The company plans to use the funds for a Phase 3 trial in acne, pre-launch activities, and advancing its TVB-3567 program.

The U.S. AURORA Phase 3 trial is set to begin in October, enrolling around 800 patients aged 12 and over. The positive market sentiment, driven by lower-than-expected inflation data, helped the stock pull back slightly from its intraday high. Analysts maintain a moderate buy rating on the stock, reflecting confidence in the denifanstat development program as it approaches a crucial clinical milestone.